After a successful appeal, reimbursement authority NICE has said the companies' files will now be sent back to the appraisal ...

February was a light month for agency and consultancy news, but a few interesting changes came through. Read on for the ...

First developed in the 1960s, they are supported by extensive clinical evidence and recommended by leading professional ...

After a strong start to the year, the value of biotech financings has tailed off a little, but March has seen a clutch of $50 ...

Axtria Ignite 2026 returns June 10–11 in Princeton, New Jersey, and this year’s theme is “Industrializing Intelligence: The Agentic Enterprise.” What does that mean? Consider this: Somewhere right now ...

Reuters Antitrust Correspondent Jody Godoy interviews FTC Bureau of Competition Director Daniel Guarnera at Reuters Pharma USA this week in Philadelphia. With patent cliffs approaching and plenty of ...

Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity, a rare condition in which damage to or a malfunction of the hypothalamus leads to excessive weight gain ...

Novartis has reached an agreement to buy a PI3K-targeting drug for breast cancer from Synnovation Therapeutics, paying a hefty $2 billion upfront for the asset, which is in phase 1/2 testing. The deal ...

It’s been an exciting time recently for Boehringer Ingelheim oncology as the company recently received FDA approval for Hernexeos (zongertinib) just 44 days after submission under the FDA’s new ...

With rapid advances in in vivo CAR‑T, gene editing, and cancer immunotherapy – alongside headline‑making acquisitions such as Eli Lilly & Orna, BMS & Orbital, AbbVie & Capstan, and BioNTech & CureVac ...

Longevity is being framed as a consumer movement when, in reality, it is a pharmaceutical pipeline challenge. And pharma isn’t treating it like one yet.

Novo Nordisk is facing generics of its GLP-1 drug in India, Atrogi is testing a new weight loss approach, and there's new ...